Kelun-Biotech to Showcase Key ADC Data at ESMO 2026

  • Kelun-Biotech will present results from multiple clinical studies at ESMO 2026, including data on sacituzumab tirumotecan (sac-TMT) and SKB500.
  • Phase III OptiTROP-Lung04 and OptiTROP-Lung06 studies for sac-TMT in NSCLC will be presented in the same time slot as proffered paper reports.
  • Global pivotal Phase III TroFuse-005 trial led by MSD will be presented for the first time in the ESMO Presidential Symposium.
  • Sac-TMT has four approved indications in China and is the world's first TROP2 ADC drug approved for marketing in lung cancer.
  • Kelun-Biotech has initiated 9 registrational clinical studies in China, while MSD has 18 ongoing global Phase III clinical studies of sac-TMT.

Kelun-Biotech's presentation at ESMO 2026 underscores its strategic focus on advancing its ADC pipeline, particularly sac-TMT, which has shown promise in multiple cancer indications. The company's collaboration with MSD for global development highlights its ambition to compete in the lucrative oncology market. The upcoming data could validate sac-TMT's potential as a key player in treating advanced solid tumors, positioning Kelun-Biotech as a significant contender in the biopharmaceutical sector.

Regulatory Progress
Whether the NMPA's priority review of sac-TMT's new indications will accelerate approval timelines and expand market access.
Clinical Efficacy
How the Phase III study results for sac-TMT in NSCLC and other cancers will impact its competitive positioning against existing therapies.
Global Expansion
The pace at which MSD can advance sac-TMT's global Phase III trials and secure regulatory approvals outside Greater China.